Jinxin Lan

Jinxin Lan

Auto-generated profile, based on publicly available information

Jinxin Lan

Medical School of Chinese PLA Beijing China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
JCJunyi Chen
Junyi Chen
YLYuyang Liu
Yuyang Liu
JLJinxin Lan
Jinxin Lan
HLHongyu Liu
Hongyu Liu
QTQingyun Tang
Qingyun Tang
LCLing Chen
Ling Chen
Background: Glioblastoma multiforme (GBM) is the most aggressive primary brain malignancy. Novel therapeutic modalities like tumor electric field therapy (TEFT) have shown promise, but underlying mechanisms remain unclear. The extracellular matrix (ECM) is implicated in GBM progression, warranting investigation into TEFT‐ECM interplay.Methods: T98G cells were treated with TEFT (200 kHz, 2.2 V/m) for 72 h. Collagen type VI alpha 1 (COL6A1) was identified as hub gene via comprehensive bioinformatic analysis based on RNA sequencing (RNA‐seq) and public glioma datasets. TEFT intervention models were established using T98G and Ln229 cell lines. Pre‐TEFT and post‐TEFT GBM tissues were collected for further validation. Focal adhesion pathway activity was assessed by western blot. Functional partners of COL6A1 were identified and validated by co‐localization and survival analysis.Results: TEFT altered ECM‐related gene expression in T98G cells, including the hub gene COL6A1. COL6A1 was upregulated in GBM and associated with poor prognosis. Muti‐database GBM single‐cell analysis revealed high‐COL6A1 expression predominantly in malignant cell subpopulations. Differential expression and functional enrichment analyses suggested COL6A1 might be involved in ECM organization and focal adhesion. Western blot (WB), immunofluorescence (IF), and co‐immunoprecipitation (Co‐IP) experiments revealed that TEFT significantly inhibited expression of COL6A1, hindering its interaction with ITGA5, consequently suppressing the FAK/Paxillin/AKT pathway activity. These results suggested that TEFT might exert its antitumor effects by downregulating COL6A1 and thereby inhibiting the activity of the focal adhesion pathway.Conclusion: TEFT could remodel the ECM of GBM cells by downregulating COL6A1 expression and inhibiting focal adhesion pathway. COL6A1 could interact with ITGA5 and activate the focal adhesion pathway, suggesting that it might be a potential therapeutic target mediating the antitumor effects of TEFT.

7 May 2024 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
JLJinxin Lan
Jinxin Lan
YLYuyang Liu
Yuyang Liu
JCJunyi Chen
Junyi Chen
HLHongyu Liu
Hongyu Liu
YFYaping Feng
Yaping Feng
LCLing Chen
Ling Chen
Background: Glioblastoma multiforme (GBM) is an aggressive malignant tumor with a high mortality rate and is the most prevalent primary intracranial tumor that remains incurable. The current standard treatment, which involves surgery along with concurrent radiotherapy and chemotherapy, only yields a survival time of 14–16 months. However, the introduction of tumor electric fields therapy (TEFT) has provided a glimmer of hope for patients with newly diagnosed and recurrent GBM, as it has been shown to extend the median survival time to 20 months. The combination of TEFT and other advanced therapies is a promising trend in the field of GBM, facilitated by advancements in medical technology.Aims: In this review, we provide a concise overview of the mechanism and efficacy of TEFT. In addition, we mainly discussed the innovation of TEFT and our proposed blueprint for TEFT implementation.Conclusion: Tumor electric fields therapy is an effective and highly promising treatment modality for GBM. The full therapeutic potential of TEFT can be exploited by combined with other innovative technologies and treatments.

19 August 2024 in Aging Medicine
Verified
Journal Article
Open access
JLJinxin Lan
Jinxin Lan
YRYifan Ren
Yifan Ren
GSGe Song
Ge Song
LLLu Liu
Lu Liu
MLMingyu Li
Mingyu Li
YMYaqi Ma
Yaqi Ma
Objectives: Parkinson disease (PD) is the third leading cause of mortality among middle‐aged and older individuals in China. This study aimed to explore the trends and distribution features of PD mortality in China from 2013 to 2021 and make predictions for the next few decades.Methods: Relevant data were obtained from the Chinese Center for Disease Control and Prevention Disease Surveillance Point system. The joinpoint regression model was used to evaluate trends. The R software was used to predict future trends.Results: Age‐standardized mortality rate (ASMR) of PD increased from 0.59 per 100,000 individuals to 1.22 per 100,000 individuals from 2013 to 2021, with an average annual percent change (AAPC) of 9.50 (95% CI: 8.24–10.78). The all‐age ASMR of PD were higher in male individuals than in female individuals, and ASMR increased with age. The number of deaths and ASMR increased gradually from west to east and from rural to urban areas. Furthermore, ASMR is expected to increase to 2.66 per 100,000 individuals by 2040.Conclusions: The heightened focus on the ASMR of PD among male individuals, urban areas, eastern China, and individuals aged ≥85 years has become a key determinant in further decreasing mortality, thereby exhibiting novel challenges to effective strategies for disease prevention and control.

5 January 2026 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
JCJunyi Chen
Junyi Chen
YLYuyang Liu
Yuyang Liu
QLQi Liu
Qi Liu
HLHongyu Liu
Hongyu Liu
CSCheng Sun
Cheng Sun
LCLing Chen
Ling Chen
Background: Glioblastoma (GBM) is one of the most aggressive and treatment‐resistant primary brain tumors, with the mesenchymal subtype exhibiting particularly poor prognosis. Tumor electric field therapy (TEFT) has emerged as a promising adjunctive treatment, but its underlying molecular mechanisms remain incompletely understood. Methods: GBM functional states were analyzed using CancerSEA datasets. GBM cell lines were treated with 200 kHz TEFT at 2.2 V/m for 72 h. C1R was knocked down using siRNA and shRNA. Cell morphology, migration, invasion, proliferation, and signaling pathways were assessed through various assays. Findings were validated in animal models and clinical specimens. Results: C1R was identified at the intersection of TEFT‐downregulated genes, poor prognosis markers, and functional state genes. C1R was significantly upregulated in mesenchymal GBM and strongly correlated with epithelial‐mesenchymal transition (EMT). Single‐cell RNA sequencing revealed C1R was predominantly expressed in MES‐like malignant cells with high EMT signature scores. TEFT treatment induced morphological changes from elongated spindle‐shaped to rounded epithelial‐like morphology, increased E‐cadherin expression, and decreased mesenchymal markers (N‐cadherin, Vimentin, YKL‐40). Mechanistically, TEFT suppressed the TGF‐β/SMAD2/3/STAT3 signaling pathway, downregulating C1R expression. C1R knockdown significantly reduced tumor growth in vivo, while exogenous TGF‐β restored C1R expression and reversed the mesenchymal phenotype in a dose‐ and time‐dependent manner. Conclusion: TEFT inhibits GBM progression by suppressing the TGF‐β/SMAD2/3/STAT3/C1R axis, thereby attenuating EMT and reducing tumor aggressiveness. These findings uncover a novel mechanism of TEFT and identify C1R as a potential biomarker and therapeutic target for GBM.